Leading Proxy Advisory Firm Backs Simpson Oil's Call for Board Overhaul at Parkland
Article content
Article content
GRAND CAYMAN, Cayman Islands — Simpson Oil Limited ('Simpson Oil', 'we' or 'our'), the largest shareholder of Parkland Corporation ('Parkland' or the 'Company'), holding 19.8% of the outstanding common shares, today announced that Glass, Lewis & Co. ('Glass Lewis'), a leading independent proxy advisory firm, has recommended that Parkland shareholders support meaningful boardroom change by voting for seven of its nine director nominees at the Company's Annual General Meeting (the 'Meeting' or the 'AGM') to be held on May 6, 2025.
Article content
Glass Lewis recommends that shareholders vote the GOLD proxy card to elect Monty Baker, Michael Christiansen, Mark Davis, Chris Folan, Brian Gibson, Darcy Morris, and Karen Stuckey to the Board of Directors (the 'Board').
Article content
Simpson Oil reiterates that wholesale change is required, and that only the election of ALL NINE of its highly qualified nominees will deliver the fresh leadership, governance, and accountability shareholders deserve. A clean break is needed from legacy directors like Michael Jennings—whose tenure as Board Chair has been marked by entrenchment, gamesmanship, and value destruction—and James Neate, whose skillsets are neither additive nor needed on a refreshed Board.
Article content
In its full report, Glass Lewis affirmed Simpson Oil's case for change, highlighting the magnitude and persistence of the Company's underperformance 1:
Article content
' This persistent underperformance, coupled with repeated financial and strategic execution challenges over multiple years, signals that stronger independent board oversight is necessary to drive shareholder value creation and strategic discipline.'
Article content
Beyond poor performance, Glass Lewis flagged serious governance concerns, pointing to a pattern of Board 'entrenchment' and 'gamesmanship':
Article content
'Taken individually, each of these decisions—from the accelerated 2024 AGM timing, to the decision to include Dissident Nominees on its slate without prior notice or engagement, to the lack of a universal proxy form—could be explained as defensible in isolation. Taken together, however, they reveal a consistent pattern, in our view: the board has repeatedly taken governance actions that appear more reactive than proactive, and more focused on retaining control than facilitating transparent, shareholder-focused outcomes. '
Article content
Importantly, Glass Lewis also criticized the incumbent Board's disregard for shareholder input, particularly its past unwillingness to consider strategic alternatives despite persistent underperformance. While the incumbent Board has now reactively launched a strategic review and the CEO has tendered his resignation, Glass Lewis notes:
Article content
'With a CEO succession process and strategic alternatives review now running concurrently, it is essential that the board overseeing both be viewed by shareholders and the market as credibly independent, compositionally balanced, and strategically focused. Against this backdrop, we believe that a majority refresh is necessary to realign board composition with shareholder expectations and to ensure credible, shareholder-focused oversight of these critical processes.'
Article content
Simpson Oil reaffirms that its nine-person slate is committed to pursuing a dual track process: conducting a comprehensive strategic review while simultaneously repositioning the Company for long-term success—all aligned to the goal of maximizing value for all shareholders.
Article content
We are pleased that Glass Lewis, a respected and independent advisory firm, has recognized the consistent pattern of poor governance and ineffective leadership at Parkland, and has concluded that significant boardroom change is needed.
Article content
For more information on the Simpson Oil nominees, their plan to unlock shareholder value at Parkland, and how to vote for the entire Simpson Oil slate on the GOLD Proxy Card, visit www.RefuelParkland.com. Proxy materials are also available under Parkland's SEDAR+ profile at www.sedarplus.ca, including a GOLD Proxy Card or voting instruction form. The deadline to return proxies to Simpson Oil is 5:00 p.m. (Calgary time) on Thursday, May 1, 2025.
Article content
Article content
Article content
Article content
Contacts
Article content
Media Enquiries
Longacre Square Partners
Amy Freedman / Andy Radia
SimpsonOil@longacresquare.com
Article content
Article content
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Cision Canada
2 hours ago
- Cision Canada
MetricAid Announces Appointment of Board of Directors to Support Accelerated Growth and Global Expansion
NORTH BAY, ON, Aug. 19, 2025 /CNW/ - MetricAid is proud to announce the formal appointment of its new Board of Directors. This exceptional group of industry leaders brings unparalleled expertise across healthcare, technology, operations, and corporate governance - a significant milestone as the company enters its next phase of accelerated growth and international expansion. The newly appointed Board comprises: Paul Tsaparis, former Board Chair of York University, former CEO and President of Hewlett-Packard Canada and currently a board member of Teranet, Metrolinx and Indspire. Mr. Tsaparis is a recognized leader in Canadian technology and innovation with extensive board experience in both public and private sectors. His deep understanding of growth-stage companies is a tremendous asset to MetricAid's long-term success. Eugene Roman, former Chief Technology Officer of Canadian Tire and OpenText, current Executive-in-Residence at the Schulich School of Business for AI and a renowned figure in enterprise digital transformation. Mr. Roman brings decades of experience in IT strategy, cybersecurity, and large-scale systems architecture. Dr. Mark Schweitzer, internationally respected radiologist and current Special Associate for Public Health, is planning the New School of Public Health at Wayne State University. Dr. Schweitzer offers deep clinical insight and a global healthcare perspective that aligns with MetricAid's commitment to physician-centred scheduling. Dr. Schweitzer has published more than 400 peer-reviewed papers with more than 27000 citations. Mark Fam, President & CEO of Oak Valley Health, one of Canada's leading healthcare institutions. With extensive leadership in hospital operations, Mr. Fam strengthens MetricAid's strategic alignment with public health systems and complex care environments. Warren Urquhart, currently Governance Counsel for Toronto Hydro, is licensed to practice Law in Ontario and New York. Warren sits as a current member of the Publications Advisory Board of the International Association of Privacy Professionals, directing content and coverage of global privacy law and AI Governance developments. In addition, Warren is an executive of both the Canadian Bar Association and the Ontario Bar Association's Privacy and Access to Information Bar Executive. "The calibre of leadership now guiding MetricAid is a testament to both our past performance and our future ambitions," said Lora Webb, CEO of MetricAid. "We are thrilled to welcome directors whose influence spans global healthcare, world-class technology, and high-growth operations. We are more prepared than ever to shape the future of physician scheduling." MetricAid's mission: Revolutionize Emergency Medicine Scheduling For more information or to request interviews, please contact: About MetricAid
National Post
9 hours ago
- National Post
Board Achieves Microsoft Solutions Partner Designation with Azure Certified Software for its Enterprise Planning Platform
Article content Article content BOSTON — Board, a leading Enterprise Planning Platform, today announced it has earned the Microsoft Solutions Partner designation with Certified Software for Azure, recognizing the company's proven capabilities in delivering enterprise-grade SaaS solutions on Microsoft Azure. Article content Article content This designation recognizes the Board Enterprise Planning Platform for meeting Microsoft's highest technical standards for financial planning software. It validates the platform's ability to empower customers with continuous, autonomous cloud governance—driving smarter financial strategies and streamlined operations across the enterprise. Article content 'Achieving the Certified Software for Azure designation is a major milestone in our strategic alignment with Microsoft,' said John Kelley, Global Lead, Microsoft Alliance at Board. 'We're committed to delivering secure, scalable, and compliant software solutions that help our partners and customers accelerate their strategic financial and operational planning performance.' Article content 'Board continues to demonstrate excellence as part of our ISV partner ecosystem,' comments Andrew Reid, Commercial Partner Lead Switzerland, Member of the Swiss Leadership Team, Microsoft. 'We're proud to recognize them with the Certified Software for Azure designation. This designation reflects Board's commitment to the highest standards in architecture, security, and operational performance—empowering customers with smarter, scalable, and trusted enterprise planning in the cloud.' Article content As a long-standing global Microsoft ISV (Independent Software Vendor) partner and member of the Microsoft AI Cloud Partner Program (MAICPP), Board is positioned to deepen its collaboration with Microsoft, delivering more effective support for enterprise customers and greater value through the Microsoft commercial marketplace. Article content To learn more, visit or find Board in the Azure Marketplace. About Board Board is the Enterprise Planning Platform built to accelerate business performance, enable continuous planning, and drive confident, aligned decisions. It powers more accurate forecasts with real-time visibility into enterprise and external data. It unifies finance and operations with a single source of the truth. And with AI-augmented experiences for every role, teams can continuously make smarter decisions for predictable, profitable business outcomes. That's why visionary global brands including H&M, BASF, Burberry, Toyota, Coca-Cola, HSBC, and thousands more trust Board to navigate complex markets with confidence. For more information, visit Article content Article content Article content Article content Article content
Cision Canada
11 hours ago
- Cision Canada
Medtronic announces Board appointments and shareholder value creation initiatives to advance strategic priorities
Experienced executives John Groetelaars and Bill Jellison appointed to the Board of Directors Board forms new Growth and Operating committees to sharpen focus on the company's ongoing strategic portfolio management, operational execution and capital allocation Plan to host Investor Day in 2026 Initiatives follow constructive engagement with Elliott Management GALWAY, Ireland, Aug. 19, 2025 /CNW/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced the Medtronic Board of Directors has appointed John Groetelaars and Bill Jellison as independent directors, effective immediately. Consistent with the company's commitment to shareholder value creation, and to provide enhanced focus and urgency around Medtronic's ongoing strategic portfolio management, operational improvement and capital allocation, the Board has formed the following special committees to align our governance with existing management focus areas and workstreams: The Growth Committee will be responsible for guiding the evaluation and execution of growth-accretive tuck-in M&A, organic R&D investments, and potential divestitures, including the continued execution of the recently announced plan to separate its Diabetes business. The Operating Committee will align governance with the company's initiatives to optimize operational performance, deliver margin expansion, and drive sustained earnings acceleration, including actions company management is taking to improve efficiency in its global manufacturing, supply chain, and operations. Chief Executive Officer and Chairman of the Board, Geoff Martha, will serve as Chair of both of the newly formed committees, and newly appointed directors, Groetelaars and Jellison, will also serve on one or both of the committees. "I am pleased to welcome John and Bill to the Medtronic Board of Directors – each of whom brings decades of relevant experience delivering growth as executives and directors of public companies in the medical technology industry. John's leadership managing global operations and Bill's deep financial expertise will also be valuable to the boardroom," said Geoff Martha, chairman and chief executive officer. "We are at an exciting inflection point and in a period of strong momentum, with multiple growth drivers already delivering and additional breakthrough therapies set to launch in the months ahead. With the addition of these new Board members and the formation of these two new committees, we are accelerating our strategic growth priorities and advancing the simplification and optimization of our operations. The separation of MiniMed is an example of the important steps we're taking to create a more focused and more profitable Medtronic. By sharpening our focus on high-margin growth opportunities, we are well-positioned to deliver stronger performance and greater value for patients, customers, and shareholders." Medtronic will host an Investor Day in mid-calendar year 2026 at which the company will discuss the work of the Growth Committee and Operating Committee, including Medtronic's go-forward strategic priorities and financial algorithm. Today's initiatives follow constructive dialogue with Elliott Investment Management L.P. ("Elliott"). Martha continued, "We appreciate our productive dialogue with Marc Steinberg and the Elliott team. The durable growth drivers now taking hold across several of our businesses are strengthening Medtronic's trajectory and reinforcing our conviction in the company's future. The Board believes Medtronic has the right strategies to build on this momentum and deliver sustained, superior returns for investors over the long-term." Elliott Partner Marc Steinberg said, "Our decision to become one of Medtronic's largest investors was driven by our strong conviction that the company is entering a new chapter of exceptional value creation defined by accelerating growth, operational improvement and enhanced strategic clarity. We believe Medtronic's recent innovations in some of the medical technology sector's most attractive markets have positioned the company for an inflection in organic growth. Combined with its renewed focus on portfolio simplification and improved operational execution, Medtronic is set to deliver a sustainable acceleration in earnings growth as well. Today's announcements – including the addition of new directors with deep medical technology experience and the formation of two focused Board committees – are the right steps towards realizing Medtronic's potential. We look forward to continuing our constructive partnership with Geoff Martha and the Board and to working closely together to realize this unique value-creation opportunity." Groetelaars and Jellison will be nominated to stand for election to the Board at Medtronic's 2025 Annual General Meeting of Shareholders. New Board Member Biographies John Groetelaars brings more than 30 years of global leadership experience across a broad range of medical device sectors. Most recently, Groetelaars served as interim CEO for Dentsply Sirona, having previously served in a director role for the company. Prior to Dentsply Sirona, John was President & CEO at Hillrom from May 2018 until the company's acquisition by Baxter International, Inc. in 2021. At Hillrom, he provided global leadership for a healthcare technology company with $3 billion in revenue and 10,000+ employees. Prior to joining Hillrom, Groetelaars served as executive vice president and president of the Interventional Segment at Becton, Dickinson and Company following its acquisition of C.R. Bard in December 2017. Currently, Groetelaars serves as Chairman of the Board of Directors for Zeus Industrial Products. He is also a Board member for Parexel, a global clinical research organization. Groetelaars earned a bachelor's degree in Mechanical Engineering from Kettering University and an MBA from Columbia University. William Jellison is a former medical technology executive and corporate finance expert. From 2013 to 2016, he served as the Vice President, Chief Financial Officer of Stryker Corporation, a global leader in medical technologies. Before joining Stryker, Jellison spent 15 years at Dentsply International in several leadership positions, including CFO. Jellison began his career with the Donnelly Corporation, holding multiple financial management and executive roles, including Vice President of Finance, Treasurer and Corporate Controller. Jellison currently serves as a Senior Advisor for Astor Place Holdings, the Private Equity arm of Select Equities, and consults with other companies in the medical technology industry. He serves as a director of public companies Avient Corporation and Anika Therapeutics, Inc. as well as a director of private companies Solenis and Young Innovations. Jellison received a B.A. in Business Administration from Hope College. About Medtronic Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Galway, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 95,000+ passionate people across more than 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. For more information on Medtronic (NYSE: MDT), visit and follow Medtronic on LinkedIn. Contacts: Erika Winkels Public Relations +1-763-526-8478 Ryan Weispfenning Investor Relations +1-763-505-4626 SOURCE Medtronic plc
